Abstract

The gonadotropin-releasing hormone (GnRH) controls pituitary gonadotropin biosynthesis and secretion and therefore it is indispensable in regulating reproductive function. We have studied the effects of a short term treatment (7-days) of a GnRH-agonist (GnRH-Ag) in vivo (a) on reproductive cyclicity and follicular development and (b) on peripheral gonadotropin secretion of normal cycling rat. GnRH-Ag (0.2, 1 or 5 micrograms/day), administered continuously through an osmotic minipump for 7-days, had a varied effect on ovarian cyclicity as is evident by vaginal cytology and it also decreased ovarian weight. A dose of 1 as well as 5 micrograms/day for 7-days of GnRH-Ag caused the complete demise of early and late antral follicles, whereas a dose of 0.2 microgram/day of GnRH-Ag for 7-days caused a significant decrease in the number of late antral follicles. There was a remarkable increase in the number of atretic follicles in the ovary of rats that were treated with 5 micrograms/day of GnRH-Ag for 7-days. Ovarian histology showed the predominance of corpora lutea in rats treated with 1 or 5 micrograms/day of GnRH-Ag and the interstitial cells in general appeared pycnotic. GnRH-Ag treatment significantly enhanced the serum LH secretion but FSH secretion remained unaffected. Serum PRL concentration diminished in rats that were treated with the highest dose (5 micrograms/day) of GnRH-Ag. Results from this study clearly demonstrate that GnRH-Ag treatment interferes with normal cyclicity of rats and it profoundly affects the follicular development. Therefore, it acts as an atretognic factor in the ovary.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.